{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Single+fraction+of+7+Gy&page=2", "query": { "intervention": "Single fraction of 7 Gy", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 54, "total_pages": 6, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Single+fraction+of+7+Gy&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Single+fraction+of+7+Gy&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-30T06:32:26.184Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03040999", "title": "Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Head and Neck Neoplasms" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Accelerated Fractionation (AFX) Radiotherapy", "type": "RADIATION" }, { "name": "Standard Fractionation (SFX) Radiotherapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 804, "start_date": "2017-04-05", "completion_date": "2024-08-21", "has_results": true, "last_update_posted_date": "2026-02-04", "last_synced_at": "2026-09-30T06:32:26.184Z", "location_count": 24, "location_summary": "Los Angeles, California • San Francisco, California • Santa Rosa, California + 21 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03040999" }, { "nct_id": "NCT01836432", "title": "Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pancreatic Cancer", "Pancreatic Carcinoma Non-resectable", "Locally Advanced Malignant Neoplasm" ], "interventions": [ { "name": "FOLFIRINOX", "type": "DRUG" }, { "name": "Algenpantucel-L Immunotherapy", "type": "BIOLOGICAL" }, { "name": "5-FU Chemoradiation", "type": "RADIATION" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Nab-Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "RADIATION" ], "sponsor": "NewLink Genetics Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 302, "start_date": "2013-05", "completion_date": "2017-03-24", "has_results": false, "last_update_posted_date": "2020-05-28", "last_synced_at": "2026-09-30T06:32:26.184Z", "location_count": 32, "location_summary": "Tucson, Arizona • Los Angeles, California • Sacramento, California + 28 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Stamford", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT01836432" }, { "nct_id": "NCT03516708", "title": "Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Rectal Cancer" ], "interventions": [ { "name": "Epacadostat", "type": "DRUG" }, { "name": "Short-course radiation therapy", "type": "RADIATION" }, { "name": "CAPOX chemotherapy", "type": "DRUG" }, { "name": "FOLFOX chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 49, "start_date": "2020-01-06", "completion_date": "2030-08-12", "has_results": false, "last_update_posted_date": "2026-02-11", "last_synced_at": "2026-09-30T06:32:26.184Z", "location_count": 4, "location_summary": "Orange, California • Boston, Massachusetts • Detroit, Michigan + 1 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03516708" }, { "nct_id": "NCT00561197", "title": "An Open-label, Single-center, Phase 1/ 2 Study of Chemoradiotherapy and AT-101 in Patients With Locally Advanced Esophageal or Gastroesophageal Junction Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Locally Advanced Esophageal or GE Junction Cancer" ], "interventions": [ { "name": "AT-101", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ascenta Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2007-08", "completion_date": "2010-09", "has_results": false, "last_update_posted_date": "2013-01-04", "last_synced_at": "2026-09-30T06:32:26.184Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00561197" }, { "nct_id": "NCT05190315", "title": "Chlorpromazine and Standard of Care in Glioblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma Multiforme" ], "interventions": [ { "name": "Chlorpromazine", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Mohammed Milhem", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2022-01-28", "completion_date": "2024-07-28", "has_results": false, "last_update_posted_date": "2025-09-02", "last_synced_at": "2026-09-30T06:32:26.184Z", "location_count": 1, "location_summary": "Iowa City, Iowa", "locations": [ { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT05190315" }, { "nct_id": "NCT00805961", "title": "RT, Temozolomide, and Bevacizumab Followed by Bevacizumab/Everolimus in First-line Treatment of GBM", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma Multiforme" ], "interventions": [ { "name": "Radiation therapy", "type": "RADIATION" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "SCRI Development Innovations, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 68, "start_date": "2009-01", "completion_date": "2013-05", "has_results": true, "last_update_posted_date": "2021-12-08", "last_synced_at": "2026-09-30T06:32:26.184Z", "location_count": 13, "location_summary": "Huntsville, Alabama • Fort Myers, Florida • Gainesville, Georgia + 10 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Gainesville", "state": "Georgia" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00805961" }, { "nct_id": "NCT06056310", "title": "Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "Xevinapant", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "intensity-modulated radiation therapy (IMRT)", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "EMD Serono Research & Development Institute, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2024-01-18", "completion_date": "2024-08-20", "has_results": true, "last_update_posted_date": "2025-09-29", "last_synced_at": "2026-09-30T06:32:26.184Z", "location_count": 5, "location_summary": "Miami Beach, Florida • Detroit, Michigan • The Bronx, New York + 2 more", "locations": [ { "city": "Miami Beach", "state": "Florida" }, { "city": "Detroit", "state": "Michigan" }, { "city": "The Bronx", "state": "New York" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Sioux Falls", "state": "South Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06056310" }, { "nct_id": "NCT03562273", "title": "GammaPod Registry and Quality of Life Nomogram", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Cancer Female" ], "interventions": [ { "name": "Quality Of Life Sizing Nomogram", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "University of Maryland, Baltimore", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 160, "start_date": "2019-01-03", "completion_date": "2030-12", "has_results": false, "last_update_posted_date": "2026-02-20", "last_synced_at": "2026-09-30T06:32:26.184Z", "location_count": 4, "location_summary": "Bel Air, Maryland • Columbia, Maryland • Glen Burnie, Maryland + 1 more", "locations": [ { "city": "Bel Air", "state": "Maryland" }, { "city": "Columbia", "state": "Maryland" }, { "city": "Glen Burnie", "state": "Maryland" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03562273" }, { "nct_id": "NCT06843551", "title": "The Miami \"EMPIRE\" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Pancreatic Ductal Adenocarcinoma", "Metastatic Pancreatic Cancer" ], "interventions": [ { "name": "Stereotactic Body Radiation Therapy", "type": "RADIATION" }, { "name": "Botensilimab", "type": "DRUG" }, { "name": "Balstilimab", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "Benjamin Spieler", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2025-06-18", "completion_date": "2030-08-01", "has_results": false, "last_update_posted_date": "2026-08-21", "last_synced_at": "2026-09-30T06:32:26.184Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06843551" }, { "nct_id": "NCT02516813", "title": "Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "M3814 100 mg", "type": "DRUG" }, { "name": "M3814 200 mg", "type": "DRUG" }, { "name": "M3814 300 mg", "type": "DRUG" }, { "name": "M3814 400 mg", "type": "DRUG" }, { "name": "M3814 50 mg", "type": "DRUG" }, { "name": "Fractionated RT", "type": "RADIATION" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "EMD Serono Research & Development Institute, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2015-09-15", "completion_date": "2021-11-19", "has_results": true, "last_update_posted_date": "2024-10-15", "last_synced_at": "2026-09-30T06:32:26.184Z", "location_count": 9, "location_summary": "Fresno, California • Fort Lauderdale, Florida • Miami, Florida + 6 more", "locations": [ { "city": "Fresno", "state": "California" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Billings", "state": "Montana" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02516813" } ] }